Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical reported its consolidated financial results for the nine months ending December 31, 2024, showing slight revenue stability but a decrease in core operating and net profits. Despite this, the company forecasts a significant improvement in operating and net profits for the year ending March 31, 2025, indicating strategic adjustments, including share repurchases and cancellations, to enhance shareholder value.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily engaged in the pharmaceutical industry. They specialize in eye care products, focusing on developing and distributing medications for various ophthalmic conditions.
YTD Price Performance: -1.96%
Average Trading Volume: 1,359
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.47B
For detailed information about 4536 stock, go to TipRanks’ Stock Analysis page.
